Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.96 - $4.14 $1,372 - $2,898
-700 Reduced 31.82%
1,500 $3,000
Q1 2024

May 15, 2024

BUY
$1.86 - $4.83 $3,720 - $9,660
2,000 Added 1000.0%
2,200 $8,000
Q4 2023

Feb 14, 2024

SELL
$1.12 - $1.93 $896 - $1,544
-800 Reduced 80.0%
200 $0
Q3 2023

Nov 14, 2023

BUY
$1.64 - $2.93 $1,312 - $2,344
800 Added 400.0%
1,000 $1,000
Q2 2023

Aug 14, 2023

SELL
$2.27 - $3.59 $1,135 - $1,795
-500 Reduced 71.43%
200 $0
Q4 2022

Feb 14, 2023

BUY
$2.43 - $3.7 $1,701 - $2,590
700 New
700 $1,000

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $29.2M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.